The New England journal of medicine
-
Benign breast disease is an important risk factor for breast cancer. We studied a large group of women with benign breast disease to obtain reliable estimates of this risk. ⋯ Risk factors for breast cancer after the diagnosis of benign breast disease include the histologic classification of a benign breast lesion and a family history of breast cancer.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Erlotinib in previously treated non-small-cell lung cancer.
We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy. ⋯ Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
A clinical trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations. ⋯ Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.